{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:15:19Z","timestamp":1792091719821,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T00:00:00Z","timestamp":1443398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Catumaxomab (CATU) is a trifunctional antibody approved for intraperitoneal (i.p.) treatment of malignant ascites (MA) related to carcinomas expressing the epithelial cell-adhesion molecule (EpCAM). CATU is mostly given to hospitalized patients, although outpatient treatment seems appropriate in selected individuals. This observational trial sought to obtain more detailed information regarding the feasibility of CATU in outpatients with MA related to various gynecologic tumors, including epithelial ovarian (EOC) and metastatic breast cancer (MBC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>A total of 30 patients were included, 17 with EOC, 7 with MBC, and 6 with other malignancies. The patients had failed a median of 5 (range 1\u201312) previous systemic treatments. CATU was administered via an indwelling i.p. catheter at four increasing doses (i.e., 10, 20, 50, and 150 \u00b5g) given at 4-day intervals over 2 weeks. Toxicities were scored according to the Common Terminology Criteria for Adverse Events, version 4.03. Puncture-free survival (PuFS) was calculated from the start of CATU until the next puncture for MA, death, or loss to follow-up. Overall survival (OS) was calculated from the start of CATU to death from any reason or loss to follow-up. We also investigated various clinical parameters to predict PuFS and OS. These included age, tumor type, performance status, intensity of pretreatment, presence of extraperitoneal metastases, relative lymphocyte count at baseline, patient adherence to therapy, and the patients\u2019 ability to undergo systemic treatment after CATU.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>CATU was exclusively given on an outpatient basis, and 19 patients (63.3%) received all four planned i.p. instillations. Toxicity was the reason for discontinuation in only 2 patients. Toxicity was generally manageable, with abdominal pain, nausea\/vomiting, fatigue, and fever the predominant adverse effects. Secondary hospitalization was necessary for 7 patients (23.3%), with a general deteriorated condition in 5 and fever\/infection or abdominal pain in 1 patient each. Subsequent systemic treatment was possible in 11 patients (36.7%). Only 5 patients (16.7%) required a second puncture after i.p. CATU. The median PuFS was 56 days, and the median OS was 79.5 days. Positive predictors of both PuFS and OS were performance status, absence of extraperitoneal tumor, the capability to receive all four CATU infusions, and the ability to undergo subsequent systemic treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Outpatient i.p. CATU therapy for MA related to various gynecologic carcinomas is safe and effective in producing good ascites control in most individuals, allowing for subsequent systemic therapy in a substantial proportion of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice:<\/jats:title>\n                  <jats:p>Intraperitoneal treatment with the trifunctional antibody catumaxomab (CATU) was possible in a selected population of 30 outpatients with malignant ascites due to epithelial female genital tract or breast carcinoma. Toxicity was largely manageable. Patients in good condition at baseline, without extraperitoneal tumor and\/or liver metastases, and with the ability to complete all four planned CATU instillations and the capability of undergoing subsequent systemic therapy benefited the most in terms of both puncture-free and overall survival. Outpatient i.p. CATU is safe and effective in a selected group of patients with malignant ascites due to various gynecologic malignancies and could be cost-saving compared with an inpatient approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0076","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T02:08:13Z","timestamp":1443492493000},"page":"1333-1341","source":"Crossref","is-referenced-by-count":21,"title":["Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms"],"prefix":"10.1093","volume":"20","author":[{"given":"Christian Martin","family":"Kurbacher","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany"},{"name":"Faculty of Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olympia","family":"Horn","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta Anna","family":"Kurbacher","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics II (General Gynecology and Obstetrics), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Herz","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Tabea","family":"Kurbacher","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Hildenbrand","sequence":"additional","affiliation":[{"name":"Institute of Pathology Bonn-Duisdorf, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhardt","family":"Bollmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology Bonn-Duisdorf, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,9,28]]},"reference":[{"key":"2021122309360488300_B1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: A retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122309360488300_B2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00000658-198606000-00009","article-title":"Malignant ascites. Clinical and experimental observations","volume":"203","author":"Garrison","year":"1986","journal-title":"Ann Surg"},{"key":"2021122309360488300_B3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: Systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Cancer"},{"key":"2021122309360488300_B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1191\/0269216302pm509oa","article-title":"The development of clinical guidelines on paracentesis for ascites related to malignancy","volume":"16","author":"Stephenson","year":"2002","journal-title":"Palliat Med"},{"key":"2021122309360488300_B5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF02303809","article-title":"Peritoneovenous shunts for palliation of the patient with malignant ascites","volume":"1","author":"Schumacher","year":"1994","journal-title":"Ann Surg Oncol"},{"key":"2021122309360488300_B6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/030089160208800208","article-title":"Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt","volume":"88","author":"Zanon","year":"2002","journal-title":"Tumori"},{"key":"2021122309360488300_B7","first-page":"3353","article-title":"Current and future options in the treatment of malignant ascites in ovarian cancer","volume":"29","author":"Woopen","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122309360488300_B8","first-page":"841","article-title":"Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes","volume":"25","author":"Schmitt","year":"2004","journal-title":"Int J Oncol"},{"key":"2021122309360488300_B9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6603881","article-title":"Characterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer","volume":"97","author":"Ruf","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122309360488300_B10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","article-title":"The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells","volume":"83","author":"Zeidler","year":"2000","journal-title":"Br J Cancer"},{"key":"2021122309360488300_B11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/CMAR.S14115","article-title":"Review of catumaxomab in the treatment of malignant ascites","volume":"2","author":"Sebastian","year":"2010","journal-title":"Cancer Manag Res"},{"key":"2021122309360488300_B12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ijc.21165","article-title":"Immunotherapy of malignant ascites with trifunctional antibodies","volume":"117","author":"Heiss","year":"2005","journal-title":"Int J Cancer"},{"key":"2021122309360488300_B13","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","article-title":"Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I\/II study","volume":"13","author":"Burges","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309360488300_B14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"2021122309360488300_B15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","article-title":"Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy","volume":"36","author":"Seimetz","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"suppl 1","key":"2021122309360488300_B16","first-page":"55","article-title":"Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer","volume":"5","author":"Eskander","year":"2013","journal-title":"Clin Pharmacol"},{"key":"2021122309360488300_B17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in quality of life (QoL) in patients with malignant ascites: Results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309360488300_B18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12032-014-0076-7","article-title":"Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: Results of the randomised phase IIIb CASIMAS study","volume":"31","author":"Sehouli","year":"2014","journal-title":"Med Oncol"},{"key":"2021122309360488300_B19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/ijc.26258","article-title":"Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II\/III study in patients with malignant ascites","volume":"130","author":"Ott","year":"2012","journal-title":"Int J Cancer"},{"issue":"suppl 2","key":"2021122309360488300_B20","first-page":"1013a","article-title":"Pooled analysis of two phase III studies provides prognostic indicators for clinical out-come after catumaxomab treatment for malignant ascites","volume":"49","author":"Bokemeyer","year":"2013","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"2021122309360488300_B21","first-page":"3097a","article-title":"Treatment with the trifunctional antibody catumaxomab followed by systemic chemotherapy: Results of a subgroup analysis from a phase III study in patients with relapsed ovarian cancer and malignant ascites","volume":"49","author":"Chekerov","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122309360488300_B22","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1158\/1078-0432.CCR-13-2351","article-title":"The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: Results from a phase II\/III study","volume":"20","author":"Heiss","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2021122309360488300_B23","doi-asserted-by":"crossref","first-page":"TPS3119a","DOI":"10.1200\/jco.2013.31.15_suppl.tps3119","article-title":"Results of the CARMA study to investigate catumaxomab therapy for malignant ascites related to peritoneal carcinomatosis in clinical practice","volume":"31","author":"Kurbacher","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122309360488300_B24","first-page":"1371a","article-title":"The use of catumaxomab for treatment of malignant ascites in clinical practice: Results of an observational trial","volume":"49","author":"Kurbacher","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122309360488300_B25","first-page":"103","article-title":"Palliative treatment of malignant ascites: Profile of catumaxomab","volume":"4","author":"Ammouri","year":"2010","journal-title":"Biologics"},{"key":"2021122309360488300_B26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7150\/jca.2.309","article-title":"Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (removab)","volume":"2","author":"Seimetz","year":"2011","journal-title":"J Cancer"},{"key":"2021122309360488300_B27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2012.11.013","article-title":"The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites","volume":"128","author":"Cella","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2021122309360488300_B28","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"2021122309360488300_B29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11523-012-0240-y","article-title":"Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer","volume":"8","author":"Petrelli","year":"2013","journal-title":"Target Oncol"},{"key":"2021122309360488300_B30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/1471-2407-13-618","article-title":"Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: A case report","volume":"13","author":"Bezan","year":"2013","journal-title":"BMC Cancer"},{"key":"2021122309360488300_B31","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00520-014-2557-9","article-title":"A survey of treatment approaches of malignant ascites in Germany and Austria","volume":"23","author":"Jehn","year":"2015","journal-title":"Support Care Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0076","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/11\/1333\/41868701\/oncolo_20_11_1333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/11\/1333\/41868701\/oncolo_20_11_1333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:08:21Z","timestamp":1640315301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/11\/1333\/6399681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,28]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,9,28]]},"published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0076","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,11,1]]},"published":{"date-parts":[[2015,9,28]]}}}